Cost–Effectiveness of Rivaroxaban Versus Heparins for Prevention of Venous Thromboembolism After Total Hip or Knee Surgery in Sweden

Lars Ryttberg; Alex Diamantopoulos; Fiona Forster; Michael Lees; Anina Fraschke; Ingela Björholt


Expert Rev Pharmacoeconomics Outcomes Res. 2011;11(5):601-615. 

In This Article


Rivaroxaban is a cost-effective alternative to LMWH for VTE prophylaxis after THR and TKR.

Despite the fact that economic evaluation data are not readily transferable between countries given the variability of data seen in different locations, this analysis provides a template for the cost–effectiveness of rivaroxaban in other settings in Europe. The cost–effectiveness of rivaroxaban in VTE prophylaxis would be driven universally by cost savings due to avoided events and improved patient QoL.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.